EU23CEDEC1/SES403 - Applying Pharma 4.0 To Expand Access To Biotherapeutics

Fewer than 10% of the world's population has access to biopharmaceutical therapeutics for treating chronic and life-threatening conditions as well as infectious diseases. Barriers to access include the high cost of biopharmaceuticals for payers and patients, long lead times for the development of biopharmaceutical drugs and limited access to biopharmaceutical manufacturing capacity in mid-and low-income countries. This inequity of access demands that the pharmaceutical industry apply innovative solutions that leverage Pharma 4.0 principles to develop and implement solutions to significantly reduce the cost of goods (CoGs), accelerate product development timelines and develop a distributed network of highly efficient biopharmaceutical manufacturing facilities.